Share-based Payment Arrangement, Expense of Tango Therapeutics, Inc. from 30 Sep 2020 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Tango Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 30 Sep 2020 to 30 Sep 2025.
  • Tango Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $6,625,000, a 7.7% decline year-over-year.
  • Tango Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $27,912,000, a 6.1% increase year-over-year.
  • Tango Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $28,897,000, a 51% increase from 2023.
  • Tango Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $19,079,000, a 34% increase from 2022.
  • Tango Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $14,230,000, a 82% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Tango Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $27,912,000 $6,625,000 -$553,000 -7.7% 01 Jul 2025 30 Sep 2025 10-Q 04 Nov 2025 2025 Q3
Q2 2025 $28,465,000 $6,570,000 -$968,000 -13% 01 Apr 2025 30 Jun 2025 10-Q 05 Aug 2025 2025 Q2
Q1 2025 $29,433,000 $7,255,000 +$536,000 +8% 01 Jan 2025 31 Mar 2025 10-Q 12 May 2025 2025 Q1
Q4 2024 $28,897,000 $7,462,000 +$2,583,000 +53% 01 Oct 2024 31 Dec 2024 10-K 27 Feb 2025 2024 FY
Q3 2024 $26,314,000 $7,178,000 +$2,318,000 +48% 01 Jul 2024 30 Sep 2024 10-Q 04 Nov 2025 2025 Q3
Q2 2024 $23,996,000 $7,538,000 +$2,417,000 +47% 01 Apr 2024 30 Jun 2024 10-Q 05 Aug 2025 2025 Q2
Q1 2024 $21,579,000 $6,719,000 +$2,500,000 +59% 01 Jan 2024 31 Mar 2024 10-Q 12 May 2025 2025 Q1
Q4 2023 $19,079,000 $4,879,000 +$1,094,000 +29% 01 Oct 2023 31 Dec 2023 10-K 27 Feb 2025 2024 FY
Q3 2023 $17,985,000 $4,860,000 +$1,045,000 +27% 01 Jul 2023 30 Sep 2023 10-Q 06 Nov 2024 2024 Q3
Q2 2023 $16,940,000 $5,121,000 +$1,696,000 +50% 01 Apr 2023 30 Jun 2023 10-Q 07 Aug 2024 2024 Q2
Q1 2023 $15,244,000 $4,219,000 +$1,014,000 +32% 01 Jan 2023 31 Mar 2023 10-Q 08 May 2024 2024 Q1
Q4 2022 $14,230,000 $3,785,000 +$1,528,000 +68% 01 Oct 2022 31 Dec 2022 10-K 27 Feb 2025 2024 FY
Q3 2022 $12,702,000 $3,815,000 +$385,000 +11% 01 Jul 2022 30 Sep 2022 10-Q 08 Nov 2023 2023 Q3
Q2 2022 $12,317,000 $3,425,000 +$2,229,000 +186% 01 Apr 2022 30 Jun 2022 10-Q 07 Aug 2023 2023 Q2
Q1 2022 $10,088,000 $3,205,000 +$2,255,000 +237% 01 Jan 2022 31 Mar 2022 10-Q 09 May 2023 2023 Q1
Q4 2021 $7,833,000 $2,257,000 01 Oct 2021 31 Dec 2021 10-K 27 Mar 2023 2022 FY
Q3 2021 $3,430,000 +$3,012,000 +721% 01 Jul 2021 30 Sep 2021 10-Q 10 Nov 2022 2022 Q3
Q2 2021 $1,196,000 01 Apr 2021 30 Jun 2021 10-Q 10 Aug 2022 2022 Q2
Q1 2021 $950,000 01 Jan 2021 31 Mar 2021 10-Q 11 May 2022 2022 Q1
Q3 2020 $418,000 01 Jul 2020 30 Sep 2020 10-Q 09 Nov 2021 2021 Q3

Tango Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $28,897,000 +$9,818,000 +51% 01 Jan 2024 31 Dec 2024 10-K 27 Feb 2025 2024 FY
2023 $19,079,000 +$4,849,000 +34% 01 Jan 2023 31 Dec 2023 10-K 27 Feb 2025 2024 FY
2022 $14,230,000 +$6,397,000 +82% 01 Jan 2022 31 Dec 2022 10-K 27 Feb 2025 2024 FY
2021 $7,833,000 +$6,069,000 +344% 01 Jan 2021 31 Dec 2021 10-K 27 Mar 2023 2022 FY
2020 $1,764,000 01 Jan 2020 31 Dec 2020 10-K 28 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.